DV
Dividend Vision

RNAC — Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc. (RNAC)

Total return is -97.9% over the past 10.1 years, 435.9 points behind SPY at 338.0%. Its deepest 1-year drawdown was 50.1%.

Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases and cancer, with its lead candidate Descartes-08 (an mRNA CAR-T therapy targeting BCMA) currently in Phase 2b trials for conditions including generalized myasthenia gravis and systemic lupus erythematosus. The company does not currently distribute dividends. Cartesian appeals to investors seeking exposure to early-stage biotech innovation, though clinical-stage companies carry substantial development and regulatory risks.

RNAC key facts

Asset type
Stock
Asset class
Equity
Inception date
06/22/2016
Last close
$8.84
Market cap
$238,871,712
Average volume
86398.0
Beta
0.459
Payout ratio
0.0
Forward P/E
25.0627
EPS
$-5.80